These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 8232238)

  • 21. Protein polarization is critical to stabilizing AF-2 and helix-2' domains in ligand binding to PPAR-gamma.
    Ji CG; Zhang JZ
    J Am Chem Soc; 2008 Dec; 130(50):17129-33. PubMed ID: 19007119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A molecular model for activation of a 5-hydroxytryptamine receptor.
    Osman R; Topiol S; Rubenstein L; Weinstein H
    Mol Pharmacol; 1987 Nov; 32(5):699-705. PubMed ID: 2824984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular modeling of the endogenous peptide Leu-Ser-Ala-Leu, pindolol, 5-hydroxytryptamine and their interactions with the human 5-hydroxytryptamine1B (5-HT1B) receptor.
    Kristiansen K; Edvardsen O; Dahl SG
    Recept Channels; 1998; 6(1):31-50. PubMed ID: 9664621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors.
    Parker EM; Izzarelli DG; Lewis-Higgins L; Palmer D; Shapiro RA
    J Neurochem; 1996 Nov; 67(5):2096-103. PubMed ID: 8863519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and pharmacological evaluation of 5-hydroxytryptamine(1a) receptor ligands to explore the three-dimensional structure of the receptor.
    López-Rodríguez ML; Vicente B; Deupi X; Barrondo S; Olivella M; Morcillo MJ; Behamú B; Ballesteros JA; Sallés J; Pardo L
    Mol Pharmacol; 2002 Jul; 62(1):15-21. PubMed ID: 12065750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion of the human 5-HT1D beta serotonin receptor to the rat 5-HT1B ligand-binding phenotype by Thr355Asn site directed mutagenesis.
    Metcalf MA; McGuffin RW; Hamblin MW
    Biochem Pharmacol; 1992 Nov; 44(10):1917-20. PubMed ID: 1449511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy.
    Ebersole BJ; Visiers I; Weinstein H; Sealfon SC
    Mol Pharmacol; 2003 Jan; 63(1):36-43. PubMed ID: 12488534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subunit rotation models activation of serotonin 5-HT3AB receptors by agonists.
    Maksay G; Simonyi M; Bikádi Z
    J Comput Aided Mol Des; 2004 Oct; 18(10):651-64. PubMed ID: 15849995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular dynamics of the 5-HT1a receptor and ligands.
    Sylte I; Edvardsen O; Dahl SG
    Protein Eng; 1993 Sep; 6(7):691-700. PubMed ID: 8248092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A cell membrane chromatography method for investigation of 5-hydroxytryptamine receptor-ligustilide interaction].
    Du H; Zhou N; Li J; Fan F
    Se Pu; 2015 May; 33(5):530-4. PubMed ID: 26387212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor.
    Sealfon SC; Chi L; Ebersole BJ; Rodic V; Zhang D; Ballesteros JA; Weinstein H
    J Biol Chem; 1995 Jul; 270(28):16683-8. PubMed ID: 7622478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macromolecular crowding and molecular recognition.
    Minton AP
    J Mol Recognit; 1993 Dec; 6(4):211-4. PubMed ID: 7917416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approaches to molecular modeling studies and specific application to serotonin ligands and receptors.
    Westkaemper RB; Glennon RA
    Pharmacol Biochem Behav; 1991 Dec; 40(4):1019-31. PubMed ID: 1816556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A molecular theoretical model of recognition and activation at a 5-HT receptor.
    Mercier GA; Osman R; Weinstein H
    Prog Clin Biol Res; 1989; 289():399-410. PubMed ID: 2542972
    [No Abstract]   [Full Text] [Related]  

  • 35. Lipid-helix interactions in membrane receptors.
    Zloh M; Gibbons WA
    Biochem Soc Trans; 1996 May; 24(2):305S. PubMed ID: 8736963
    [No Abstract]   [Full Text] [Related]  

  • 36. 5-Hydroxytryptamine receptor subtypes: molecular and functional diversity.
    Saudou F; Hen R
    Adv Pharmacol; 1994; 30():327-80. PubMed ID: 7833295
    [No Abstract]   [Full Text] [Related]  

  • 37. Conditions for the existence of critical points in Scatchard plots of binding results.
    Baghurst PA; Nichol LW; Winzor DJ
    J Theor Biol; 1978 Oct; 74(4):523-34. PubMed ID: 732342
    [No Abstract]   [Full Text] [Related]  

  • 38. Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs.
    Klein LM; Cozzi NV; Daley PF; Brandt SD; Halberstadt AL
    Neuropharmacology; 2018 Nov; 142():231-239. PubMed ID: 29499272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of threonine 342 in helix 7 of the 5-hydroxytryptamine type 1D receptor in ligand binding: an indirect mechanism for receptor selectivity.
    Smolyar A; Osman R
    Mol Pharmacol; 1993 Oct; 44(4):882-5. PubMed ID: 8232238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus.
    Almaula N; Ebersole BJ; Ballesteros JA; Weinstein H; Sealfon SC
    Mol Pharmacol; 1996 Jul; 50(1):34-42. PubMed ID: 8700116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.